SpyGlass Pharma has announced the completion of enrollment in its Phase I/II clinical trial (NCT06120842) evaluating its long-term drug delivery platform for patients with glaucoma or ocular hypertension. The platform is designed to deliver bimatoprost over a period of three years to lower intraocular pressure (IOP). The implant is administered during routine cataract surgery.
Patrick Mooney, CEO of SpyGlass Pharma, emphasized the impact of chronic eye conditions on patients' lives, stating, "Chronic eye conditions, such as glaucoma, can lead to vision loss and significantly impact quality of life. That’s why SpyGlass is singularly focused on making a difference for those in need." He also noted the importance of this milestone in bringing the SpyGlass technology to a wider patient population and the company's plans to engage with the FDA as they move towards Phase III trials.
Potential for Expanded Glaucoma Treatment
Dr. Malik Kahook, co-founder of SpyGlass Pharma, highlighted the potential of the platform to improve glaucoma care during routine cataract surgery. "As the SpyGlass platform is implanted using standard surgical techniques, it could significantly expand the integration of glaucoma treatment into routine cataract procedures," Kahook explained. "This could enhance adoption across a broad spectrum of surgeons and practices, setting our platform apart from currently available glaucoma interventions."
Study Details and Future Data Release
The SpyGlass Drug Delivery Platform is designed to deliver bimatoprost to targeted tissues over three years. The company plans to release data from the Phase I/II study, as well as from their recently published first-in-human study with 18-month data, as it becomes available.
